The Features of a Humoral Immune Response Development during the Acute Phase of ixodes Tick-Borne Borreliosis (Based on Multiplex Analysis with the Immunochip)

The features of development of IgM or IgG immune responses to Borrelia antigens (C6, OspC and VlsE) were studied in 155 patients with localized and disseminated stages of disease with Ixodid Tick-borne Borrelioses (ITBB), the cases of mixed infection with ITBB and human granulocytic anaplasmosis (HGA) including. Patient sera (n = 373) were examined by a multiplex microarray immunoassay test (PHOSPHAN^TM). At the localized stage of the disease, a positive PHOSPHAN reaction with C6 from B. burgdorferi was observed significantly more frequently in tests for IgG than for IgM at almost all times after tick bite, except for the first week. The frequency of positive samples in tests for both IgM and IgG was higher than for IgG alone, although the difference lacked statistical significance. Positive reactions with OspC or VlsE were observed only in the samples from patients that were also positive for IgM and/or IgG to C6. Therefore, additional detection of IgM to recombinant proteins did not improve significantly the overall sensitivity of the latter PHOSPHAN variant. As compared with ITBB monoinfection, the frequency of positive samples in patients with mixed ITBB + HGA infection was significantly higher (p < 0.05). At the disseminated stage of the disease, the proportion of positive reactions with any of Borrelia antigens for IgM was comparable or higher than for C6-IgG that resulted in a substantial number of patients with negative reactions for IgG; this necessitates the use of alternative methods (e.g., PCR) to exclude false-positive serologic results.

иксодовые клещевые боррелиозы, локализованная и диссеминированная стадии заболевания, микст-инфекция с гранулоцитарным анаплазмозом человека, гуморальный иммунитет, мультиплексный иммуночиповый анализ ФОСФАН™, пептид С6, рекомбинантные белки OspC и VlsE, ixodid tick-borne borrelioses (ITBB), localized and disseminated stages of disease with ITBB, coinfection with ITBB and HGA, multiplex microarray immunoassay PHOSPHAN^TM, IgM and IgG to Borrelia antigens, C6 peptide, recombinant proteins OspC and VlsE

1. Aguero-Rosenfeld M.E., Wang G., Schwartz I., Wormser G.P. Diagnosis of Lyme borreliosis // Clin. Microbiol. Rev. 2005; 18: 484 – 509.

2. Wilske B., Fingerle V., Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS immunology and medical microbiology. 2007; 49: 13 – 21.

3. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S. et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2006; 43: 1089 – 1134.

4. Bacon R.M., Biggerstaff B.J., Schriefer M.E., Gilmore R.D., Philipp M.T., Steere A.C. et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J. Infect. Dis. 2003; 187: 1187 – 1199.

5. Burbelo P.D., Issa A.T., Ching K.H., Cohen J.I., Iadarola M.J., Marques A. Rapid, simple, quantitative and highly sensitive antibody detection for Lyme disease. Clin. Vaccine Immunol. 2010; 17: 904 – 909.

6. Pomelova V.G., Korenberg E.I., Osin N.S., Bychenkova N.A., Bekman N.I., Kanaeva T.A. et al. The use of microarray-based phosphorescent immunoassay tests for serologic diagnosis of ixodid tick-borne borrelioses. Epidemiology and Vaccine Prophylactics 2010; 1: 22 – 29 (in Russian).

7. Porwancher R.H., Hagerly C.G., Fan J., Landsberg L., Johnson B.J.B., Kopnitsky M. et al. Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10- IgM antibodies: improving test performance through bioinformatics. Clin. Vaccine Immunol. 2011; 18: 851 – 859.

8. Tchekanova T.A., Markelov M.L., Karan’ L.S., Ushakova M.A., Pudova E.A., Romashkina A.S. et al. The new possibilities in serologic diagnostics of ixodid tickborne borreloses using immunochip. Clin. Lab. Diagn. 2013; 12: 51 – 55 (in Russian).

9. Liang F.T., Steere A.C., Marques A.R., Johnson B.J.B., Miller J.N., Philipp M.T. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE. J. Clin. Microbiol. 1999; 37: 3990 – 3996.

10. Strle F., Stanek G. Clinical manifestation and diagnosis of Lyme Borreliosis. In: Lyme Borreliosis (Eds.: D. Lipsker and B. Jaulhac). Basel: Karger. Curr. Probl. Dermatol. 2009; 37: 51 – 110.

11. Goettner G., Schulte-Spechtel U., Hillermann R., Liegl G., Wilske B., Fingerle V. Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. J. Clin. Microbiol. 2005; 43: 3602 – 3609.

12. Branda J.A., Aguero-Rosenfeld M.E., Ferraro M.J., Johnson B.J.B., Wormser G.P., Steere A.C. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin. Infect. Dis. 2010; 50: 20 – 26.

13. Wormser G.P., Schriefer M., Aguero-Rosenfeld M.E., Levin A., Steere A.C., Nadelman R.B., Nowakowski J., Marques A., Johnson B.J., Dumler J.S. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 9 – 15.

14. Branda J.A., Strle F., Strle K., Sikand N., Ferraro M.J., Steere A.C. Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin. Infect. Dis. 2013; 57: 333 – 340.

15. Wormser G.P., Tang A.T., Schimmoeller N.R., Bittker S., Cooper D., Visintainer P. et al. Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vise versa. Med. Microbiol. Immunol. 2014; 203: 65 – 71.

16. Krupka I., Knauer J., Lorentzen L., O’Connor T.P., Saucier J., Straubinger R.K. Borrelia burgdorferi sensu lato species in Europe induce diverse immune responses against C6 peptides in infected mice. Clin.Vaccine Immunol. 2009; 16: 1546 – 1562.

17. Sillanpaa H., Lahdenne P., Sarvas H., Arnez M., Steere A., Peltomaa M. et al. Immune responses to borrelial VlsE IR6 peptide variants. Int. J. Med. Microbiol. 2007; 297: 45 – 52.

18. Osin N.S., Pomelova V.G. Multi-array immunophosphorescence technology for the detection of pathogens. In: Frontiers in research. National Institute of Allergy and Infectious Diseases, NIH (Eds.: V.St. Georgiev, K.A. Western, J.J. McGowan). Totowa, NY: Humana Press; 2008: 233 – 240.

19. Pomelova V.G., Korenberg E.I., Osin N.S., Bychenkova N.A., Bekman N.I., Kanaeva T.A. et al. Prospects of natural foci infections serodiagnosis using the multiplexed phosphorescent immunoassay: Proceedings of the All-Russian conference with international participation celebrated to the 70th anniversary of Academician E.N. Pavlovskii’s theory on natural focality of diseases: Actual problems of natural focality of diseases. Omsk: Omsk scientific vestnik. 2009: 61 – 63 (in Russian).

20. Embers M.E., Hasenkampf N.R., Jacobs M.B., Phillip M.T. Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques. Clin. Vaccine Immunol. 2012; 19: 1218 – 1226.

21. Aberer E., Schwantzer G. Course of antibody response in Lyme borreliosis patients before and after therapy. ISRN Immunology. 2012; 1 – 4. doi:10.5402/2012/719821

22. Vorobyova N.N. Clinical manifestations, treatment, and prophylactics of ixodid tick-borne borrelioses. Perm’: Ural Press; 1998 (in Russian).

23. Vorobyova N.N., Syumlivaya O.N. Clinical variants of ixodid tick-borne borrelioses in acute period of disease. Medical Parasitology and Parasitic Diseases. 2003; 4: 3 – 7 (in Russian).

24. Embers M.E., Jacobs M.B., Johnson B.J.B., Philipp M.T. Dominant epitopes of the C6 diagnostic peptide of Borrelia burgdorferi are largely inaccessible to antibody on the parent VlsE molecule. Clin. Vaccine Immunol. 2007; 14: 931 – 936.

25. Jones D.D., DeIulio G.A., Winslow G.M. Antigen-driven induction of polyreactive IgM during intracellular bacterial infection. J. Immunol. 2012; 189: 1440 – 1447.

26. Philipp M.T., Bowers L.C., Fawcett P.T., Jacobs M.B., Liang F.T., Marcues A.R. et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J. Infect. Dis. 2001; 184: 870 – 878.